Inventisbio Co. Ltd. and Inventisbio LLC have divulged Werner syndrome helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Jazz Pharmaceuticals Ireland Ltd. has identified compounds acting as GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.
Insmed Inc. has synthesized cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, cancer, chronic rhinosinusitis, heart failure, inflammatory bowel disease, psoriasis and thrombosis, among others.
Certa Therapeutics Pty Ltd. has disclosed ovarian cancer G-protein coupled receptor 1 (GPR68; OGR1) antagonists reported to be useful for the treatment of cancer, inflammation and fibrosis.
Cardiac hypertrophy is a main contributor to heart failure, where therapeutic options are limited. Increasing evidence exists regarding up-regulation of histone lysine-specific demethylase 4A (KDM4A) in patients with cardiac hypertrophy as a risk factor, although the mechanisms behind are not well understood.
Duchenne muscular dystrophy is the most frequent inherited muscle disease and no cure is available. The condition is currently treated with corticosteroids, which can cause substantial side effects.
Oncolytic viruses are being actively explored as cancer therapies because they preferentially infect tumor cells and cause their lysis. At the same time, the viruses can accommodate transgenes that can stimulate anti-cancer responses in the local tumor microenvironment.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded Baxiva AG $3 million to develop its multivalent glycoconjugate vaccine.
Researchers from Arkansas State University synthesized a library of thiazole derivatives, and these compounds were subsequently screened for their antibacterial activity both in vitro and in vivo.
RSS
